
Italia
Maggiori informazioni ?
Contattaci
You are here
First-Half 2020 Results
02 Settembre, 2020- Organic sales growth of 15.7% in first-half 2020:
- €1,476 million in sales
- Up 15.8% as reported
- As expected, a mixed sales performance, with faster momentum in molecular biology solutions contrasting with a slowdown in microbiology, immunoassays and industrial applications
- Robust growth in contributive operating income before non-recurring items, to €253 million, or 17.1% of sales
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In today’s unprecedented health crisis, bioMérieux’s positioning as a specialist in infectious disease diagnostics takes on all of its meaning and allowed to rapidly provide high-performance solutions for diagnosing COVID-19. Despite the pandemic’s negative impact on certain product lines and taking into account health and economic conditions, bioMérieux is expected to deliver a remarkable performance this year. However, this performance is not projectable beyond 2020.”
Pioneering diagnostics
- Chi Siamo
- Diagnostica Clinica
- Microbiologia Industriale
- News
- Servizi
- PREFERITI
- Regione Adriatica
bioMérieux Italia Spa | Sede Legale Via di Campigliano, 58 Loc.Ponte a Ema
50012 Bagno a Ripoli (FI) Italia | Capitale Sociale € 9.000.000 i.v. Socio Unico
n.REA FI 443558 | C.F. 07146020586 | P.IVA 01696821006
- Note Legali
- Privacy
- Protocollo Cookies
- Mappa del sito
- Contatti
- Copyright 2018 bioMérieux SA